VALEO PHARMA INC.CL.A

Valeo reports 2025 revenue of €20.9bn (+0.5% like‑for‑like) and an operating margin of 4.7%. Free cash flow after net finance costs rose to a record €371m (+50%); adjusted EBITDA margin was 14.7% and net income attributable to shareholders was €200m. Order intake amounted to €24.6bn, with strong momentum in China, while net debt fell to €4.0bn. For 2026 Valeo expects revenue of €20–21bn, an operating margin of 4.7–5.3% and free cash flow after net finance costs of over €400m; risks remain market volatility, challenges in China and high tax burdens. » Más en de.investing.com

Valeo presented the strategy plan “Elevate 2028”, targeting €22–24 billion in revenue by 2028, an operating margin of 6–7% and free cash flow after interest of at least €500 million. The company aims to reduce its leverage to below 1.0x adjusted EBITDA and pursue an investment‑grade rating by 2028. For 2025 Valeo confirmed revenue, adjusted-EBITDA and margin targets and raised its pre-interest free cash flow forecast to slightly above €550 million; CEO Christophe Perillat cited three growth levers and a focus on electrified, safe and software-defined vehicles as well as expansion in China, India and North America. » Más en de.investing.com

Valeo CEO Christophe Perillat warned at the IAA that automotive equipment produced in China can be up to 30 percent cheaper and that cheap Chinese imports could undermine competitiveness and jobs in Europe. Valeo stresses that it produces locally but is calling on the European Commission for support and for minimum shares of European content in vehicles sold in the EU to secure production in Europe. The company notes that the declining share of European parts further burdens the industry, since the shift to electric vehicles has already reduced jobs. » Más en de.investing.com